Check-Cap (STU:7CC) Moat Score: 4/10 (As of Jul. 06, 2026)


STU:7CC Check-Cap Ltd STU:7CC
25 GF Score
Price €0.99
! 2 Warning Signs
View Full Analysis

What is Check-Cap Moat Score?

Check-Cap STU:7CC +3.14% 25 Moat Score is 4 as of Jul. 06, 2026. GuruFocus rates STU:7CC with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Check-Cap ranks better than 82.95% on this metric.

Check-Cap has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Check-Cap has Narrow Moat: Check-Cap Ltd has a discernible moat due to its innovative medical technology and some regulatory barriers. However, the company faces intense competition and lacks strong brand strength or significant customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Check-Cap might have Narrow Moat - Discernible but modest moat.

Check-Cap  (STU:7CC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Check-Cap Moat Score Related Terms

STU:7CC vs ADVB, XWEL, NDRA: Moat Score Comparison

For the Diagnostics & Research subindustry, Check-Cap's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Check-Cap Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Moat Score distribution charts can be found below:

* The bar in red indicates where Check-Cap's Moat Score falls into.


STU:7CC
25GF Score
Check-Cap Ltd STU:7CC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Check-Cap (STU:7CC) has a Moat Score of 4 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Check-Cap ranks #37 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 17.1%.
Is Check-Cap's Moat Score too high?
Check-Cap's current Moat Score is 4. Based on the distribution chart, Check-Cap ranks #37 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Check-Cap has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's Moat Score compare to ADVB and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #37 out of 217 companies for Moat Score. This places Check-Cap in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Check-Cap's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current Moat Score of 4. The current Moat Score is 4. Check-Cap's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current Moat Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Check-Cap Business Description

Other Exchanges MBAI:USA
Address 29 Abba Hushi Avenue, P.O. Box 1271, Mount Carmel, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
25GF Score

Get the complete analysis for STU:7CC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price